Cost-effectiveness of Nusinersen for Spinal Muscular Atrophy-Reply
JAMA Pediatr
.
2018 Jul 1;172(7):701-702.
doi: 10.1001/jamapediatrics.2018.0733.
Author
Vinay Prasad
1
Affiliation
1
Center for Health Care Ethics, Division of Hematology and Medical Oncology, Department of Preventive Medicine and Public Health, Knight Cancer Institute, Oregon Health and Science University, Portland.
PMID:
29800980
DOI:
10.1001/jamapediatrics.2018.0733
No abstract available
Publication types
Letter
Comment
MeSH terms
Cost-Benefit Analysis
Humans
Morals
Muscular Atrophy, Spinal*
Oligonucleotides*
Substances
Oligonucleotides
nusinersen